MICROBIOTA ( DrugBank: - )


1 disease
IDDisease name (Link within this page)Number of trials
96Crohn disease23

96. Crohn disease


Clinical trials : 2,400 Drugs : 1,391 - (DrugBank : 267) / Drug target genes : 170 - Drug target pathways : 215
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03747718
(ClinicalTrials.gov)
December 1, 20228/3/2018Randomized Trial Comparing Single vs. Maintenance Fecal Microbiota Transplant for Refractory Crohn's Disease in ChildrenA Study for Evaluation of Clinical Response to Single vs. Maintenance Fecal Microbiota Transplantation in Pediatric Patients With Refractory Crohn's DiseaseCrohn DiseaseBiological: Fecal Microbiota Transplantation;Other: PlaceboStanford UniversityNULLNot yet recruiting2 Years25 YearsAll30Phase 1United States
2NCT05248191
(ClinicalTrials.gov)
April 1, 20229/2/2022FMT for Postop Crohn's DiseaseFecal Microbiota Transplant for Postoperative Crohn's DiseaseCrohn DiseaseBiological: Capsule fecal microbiota material (cap-FMT);Biological: Colonoscopic fecal microbiota material (colo-FMT)University of MinnesotaNULLNot yet recruiting18 YearsN/AAll30Phase 1United States
3NCT04924270
(ClinicalTrials.gov)
January 20227/6/2021Safety and Efficacy of Faecal Microbiota Transplantation in Treatment-naïve Patients With Newly Diagnosed Chronic Inflammatory DiseasesSafety and Clinical Efficacy Associated With Faecal Microbiota Transplantation Performed in Treatment-naïve Patients With Newly Diagnosed Rheumatoid Arthritis, Reactive Arthritis, Ankylosing Spondylitis, Psoriatic Arthritis, Gouty Arthritis, Psoriasis, Hidradenitis Suppurativa, Pulmonary Sarcoidosis, Crohn's Disease, and Ulcerative Colitis: a 52-week, Double-blind, Randomised, Placebo-controlled, Exploratory TrialRheumatoid Arthritis;Reactive Arthritis;Ankylosing Spondylitis;Psoriatic Arthritis;Gouty Arthritis;Psoriasis;Hidradenitis Suppurativa;Pulmonary Sarcoidosis;Crohn Disease;Ulcerative ColitisBiological: Faecal microbiota transplantation;Other: PlaceboTorkell EllingsenRegion of Southern Denmark;University of Southern DenmarkNot yet recruiting18 Years70 YearsAll200Phase 2NULL
4NCT04997733
(ClinicalTrials.gov)
September 22, 20215/7/2021Fecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF WithdrawalFecal Microbiota Transplantation in Crohn's Disease as Relay After Anti-TNF WithdrawalCrohn DiseaseDrug: Fecal Microbiota Transplantation (FMT);Drug: Sham-transplantation (placebo)Assistance Publique - Hôpitaux de ParisCRB-HUEP;Institut National de la Santé Et de la Recherche Médicale, FranceRecruiting18 Years74 YearsAll150Phase 3France
5NCT04970446
(ClinicalTrials.gov)
August 1, 202118/7/2021The MIRO II Study: Microbial Restoration in Inflammatory Bowel DiseasesThe MIRO II Study: Microbial Restoration in Inflammatory Bowel DiseasesFecal Microbiota Transplantation;Crohn Disease;Inflammatory Bowel Diseases;MicrobiomeDrug: Antibiotics;Dietary Supplement: Dietician designed diet;Drug: FMT;Other: PlaceboSt Vincent's Hospital MelbourneThe Queen Elizabeth Hospital;BiomeBank Adelaide;The University of Queensland;Monash UniversityNot yet recruiting18 Years70 YearsAll120Phase 2/Phase 3NULL
6EUCTR2019-003816-29-FR
(EUCTR)
16/12/201914/10/2019Fecal microbiota transplantation in Crohn’s disease as relay after anti-TNF withdrawalFecal microbiota transplantation in Crohn’s disease as relay after anti-TNF withdrawal - MIRACLE Adult patients with Crohn’s disease diagnosed for at least 6 months and healthy volunteers donors
MedDRA version: 20.0;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders ;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]
Product Name: Fecal microbiota
Product Name: Fecal microbiota
ASSISTANCE PUBLIQUE -HOPITAUX DE PARIS (AP-HP)NULLAuthorised-recruitment may be ongoing or finished Female: yes
Male: yes
200 Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): yes Therapeutic use (Phase 4): noFrance
7NCT03378167
(ClinicalTrials.gov)
December 1, 201812/12/2017PediCRaFT: Pediatric Crohn's Disease Fecal Transplant TrialPediCRaFT: Pediatric Crohn's Disease Fecal Microbiota Transplant Pilot StudyCrohn Disease;Pediatric Crohns Disease;Inflammatory Bowel Diseases;ColitisBiological: MICROBIOTA;Biological: PLACEBOMcMaster Children's HospitalHamilton Health Sciences Corporation;McMaster UniversityRecruiting3 Years17 YearsAll45Phase 1Canada
8NCT03476317
(ClinicalTrials.gov)
July 12, 20188/1/2018Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseAn Open-Label Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseCrohn DiseaseDrug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: FluconazoleChildren's Hospital of PhiladelphiaUniversity of Pennsylvania;National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Completed6 YearsN/AAll10Phase 2United States
9NCT03477032
(ClinicalTrials.gov)
June 1, 201819/3/2018FMT in Inflammatory Bowel DiseaseFaecal Transplantation in Inflammatory Bowel DiseaseFaecal Microbiota Transplantation;Crohn Disease;Ulcerative Colitis;Microscopic ColitisBiological: Faecal Microbiota TransplantationSt Vincent's Hospital MelbourneNULLRecruiting18 Years65 YearsAll50Australia
10NCT02330211
(ClinicalTrials.gov)
July 17, 201729/12/2014Fecal Microbiota Transplant (FMT) in Pediatric Active Crohn's ColitisA Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Crohn's ColitisInflammatory Bowel Diseases;Crohn DiseaseBiological: Fecal Microbiota Transplant;Biological: PlaceboStacy A. KahnNULLCompleted5 Years30 YearsAll4Phase 1/Phase 2United States
11NCT03078803
(ClinicalTrials.gov)
March 28, 201712/1/2017Fecal Transplant for Crohn's DiseaseA Prospective Multicenter Randomized Controlled Trial Comparing Fecal Microbiota Transplantation (FMT) to Placebo in the Treatment of Mild to Moderate Crohn's DiseaseCrohn DiseaseBiological: Fecal Microbiota Transplant (FMT);Biological: PlaceboUniversity of AlbertaUniversity of Calgary;McMaster UniversityRecruiting18 YearsN/AAll126Phase 2Canada
12NCT03755583
(ClinicalTrials.gov)
February 1, 201718/11/2018Effect of Exclusive Enteral Nutrition on Disease Process, Nutritional Status and Gastrointestinal Microbiota for Chinese Children With Crohn's DiseaseEffect of Exclusive Enteral Nutrition on Disease Process, Nutritional Status and Intestinal Microbiota for Chinese Children With Crohn's DiseaseCrohn Disease;Enteral Nutrition;Gastrointestinal MicrobiomeDietary Supplement: Exclusive Enteral NutritionChildren's Hospital of Fudan UniversityNULLCompleted1 Year17 YearsAll31N/AChina
13NCT02765256
(ClinicalTrials.gov)
August 20162/5/2016Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseFundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's DiseaseCrohn's DiseaseDrug: Fluconazole;Drug: Vancomycin;Drug: Neomycin;Drug: Ciprofloxacin;Drug: Polyethylene Glycol 3350;Drug: Promethazine;Drug: Fluconazole placeboUniversity of PennsylvaniaChildren's Hospital of Philadelphia;Crohn's and Colitis FoundationCompleted18 Years75 YearsAll8Phase 2United States
14NCT02897661
(ClinicalTrials.gov)
August 201614/8/2016Washed Microbiota Transplantation Improves Nutritional Status of Patients With Crohn's DiseaseWashed Microbiota Transplantation Combining Exclusive Enteral Nutrition Contribute to Nutritional Improvement of Patients With Crohns' DiseaseCrohn's DiseasesProcedure: WMT;Dietary Supplement: EENThe Second Hospital of Nanjing Medical UniversityNULLRecruiting18 Years65 YearsAll30N/AChina
15NCT02636517
(ClinicalTrials.gov)
December 201516/12/2015Fecal Microbiome TransplantFecal Microbiome Transplant in Pediatric C. DifficileClostridium Difficile;Inflammatory Bowel Disease;Crohn's Disease;Ulcerative ColitisBiological: Fecal Microbiota TransplantChildren's Hospital of PhiladelphiaNULLActive, not recruiting3 Years21 YearsAll250N/AUnited States
16NCT02330653
(ClinicalTrials.gov)
November 201529/12/2014Fecal Microbiota Transplant (FMT) in Pediatric Active Ulcerative Colitis and Pediatric Active Crohn's ColitisA Phase I/II, Double Blinded, Placebo Controlled, Single-center Study of Fecal Microbiota Transplant (FMT) for the Treatment of Active Pediatric Ulcerative Colitis and Pediatric Active Crohn's ColitisInflammatory Bowel Diseases;Ulcerative Colitis;Crohn DiseaseBiological: Fecal Microbiota Transplant (FMT);Biological: PlaceboStacy A. KahnNULLCompleted5 Years30 YearsAll15Phase 1/Phase 2United States
17NCT02417974
(ClinicalTrials.gov)
September 20151/4/2015Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)Prevention of Recurrence of Crohn's Disease by Fecal Microbiota Therapy (FMT)Crohn's DiseaseBiological: Fecal Microbiota Transplant (FMT)Boston Medical CenterBrigham and Women's Hospital;Beth Israel Deaconess Medical Center;Massachusetts Institute of TechnologyTerminated18 YearsN/AAll30Phase 2United States
18NCT02575040
(ClinicalTrials.gov)
May 20156/10/2015Efficacy of Fecal Microbiota Transplantation for Inflammatory Bowel DiseaseEfficacy of Fecal Microbiota Transplantation for Refractory Inflammatory Bowel DiseaseUlcerative Colitis;Crohn Disease;Constipation (Excl Faecal Impaction)Biological: Fecal microbiota transplantationGulhane Military Medical AcademyNULLRecruiting18 YearsN/ABoth60Phase 3Turkey
19NCT02335281
(ClinicalTrials.gov)
January 20157/1/2015Standardized Fecal Microbiota Transplantation for Inflammatory Bowel DiseaseEfficacy, Durability and Safety of Standardized Fecal Microbiota Transplantation for Severe Inflammatory Bowel DiseaseInflammatory Bowel Disease;Ulcerative Colitis;Crohn's DiseaseProcedure: FMT;Drug: MesalazineYanling WeiNULLRecruiting16 Years70 YearsBoth40Phase 2China
20NCT02426567
(ClinicalTrials.gov)
November 201417/4/2015The Impact of Crohn's Disease-TReatment-with-EATing Diet and Exclusive Enteral Nutrition on Healthy Gut BacteriaAn Exploratory Study on the Impact of a Food-based Restrictive Diet (Crohn's Disease-TReatment-with EATing/CD-TREAT Diet) and Liquid Exclusive Enteral Nutrition (EEN) on Healthy Gut Microbiota Composition and Metabolic ActivityCrohn's Disease;Dietary ModificationOther: Exclusive Enteral Nutrition (EEN);Other: Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)University of GlasgowNULLCompleted18 YearsN/ABoth28N/AUnited Kingdom
21NCT02199561
(ClinicalTrials.gov)
July 201422/7/2014Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's DiseaseA Prospective, Single Center, Open Label Trial of Fecal Microbiota Transplantation (FMT) in the Management of Active Crohn's DiseaseCrohn's DiseaseBiological: Fecal Microbiota TransplantUniversity of AlbertaNULLCompleted18 Years65 YearsBoth3Phase 1/Phase 2Canada
22NCT02108821
(ClinicalTrials.gov)
March 201421/3/2014Fecal Microbiota Transplantation in Pediatric PatientsA Study of Fecal Microbiota Transplantation in Pediatric Patients With Relapsed Inflammatory Bowel Disease.Inflammatory Bowel Diseases (IBD);Crohn's Disease (CD);Ulcerative Colitis (UC)Biological: Fecal Microbiota Transplantation (FMT)Children's Mercy Hospital Kansas CityUniversity of Pittsburgh;Stanford UniversityCompleted2 Years22 YearsAll23Phase 1United States
23NCT01632462
(ClinicalTrials.gov)
September 201225/6/2012A Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseA Prospective, Placebo Controlled, Double-Blind, Cross-over Study on the Effects of a Probiotic Preparation (VSL#3) on Metabolic Profile, Intestinal Permeability, Microbiota, Cytokines and Chemokines Expression and Other Inflammatory Markers in Pediatric Patients With Crohn's DiseaseCrohn's DiseaseDrug: VSL#3Federico II UniversityNULLRecruiting5 Years17 YearsBoth30Phase 4Italy